Roche adds to Genentech's ophthalmology program with $670M in biobucks for Lineage Cell Therapeutics' asset

Roche’s Genentech has signed what could be a $670 million deal for Lineage Cell Therapeutics’ cell therapy for a range of eye disorders.

Lineage is developing a retinal pigment epithelium cell therapy in dry age-related macular degeneration (dry AMD) with geographic atrophy. The treatment, dubbed OpRegen, is currently in a phase 1/2 study for the eye disorder. The small biotech will complete work on that study and hand things over to Genentech.